This application is part of a joint application for continuation of funding for The Trial to Reduce Alloimmunization to Platelets or TRAP. This is a multicenter trial with seven clinical centers and a Coordinating Center participating. The trial seeks to evaluate three alternative methods of platelet product preparation with respect to their ability to reduce or eliminate alloimmunization to platelet and/or HLA antigens and the refractory state.
| Slichter, Sherrill J; Bolgiano, Douglas; Kao, Kuo-Jang et al. (2011) Persistence of lymphocytotoxic antibodies in patients in the trial to reduce alloimmunization to platelets: implications for using modified blood products. Transfus Med Rev 25:102-10 |
| Slichter, Sherrill J; Davis, Kathryn; Enright, Helen et al. (2005) Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients. Blood 105:4106-14 |
| Enright, Helen; Davis, Kathryn; Gernsheimer, Terry et al. (2003) Factors influencing moderate to severe reactions to PLT transfusions: experience of the TRAP multicenter clinical trial. Transfusion 43:1545-52 |
